Titre : Molécules d'interaction stromale

Molécules d'interaction stromale : Questions médicales fréquentes

Termes MeSH sélectionnés :

Urodynamics

Questions fréquentes et termes MeSH associés

Diagnostic 5

#1

Comment diagnostiquer une interaction stromale ?

Des biopsies et des analyses immunohistochimiques sont utilisées pour évaluer les interactions stromales.
Biopsie Immunohistochimie
#2

Quels tests sont utilisés pour les molécules stromales ?

Les tests ELISA et les western blots permettent de quantifier les molécules d'interaction stromale.
Test ELISA Western Blot
#3

Les marqueurs stromaux sont-ils spécifiques ?

Certains marqueurs peuvent être spécifiques à des types de tumeurs, mais d'autres sont plus généraux.
Marqueurs tumoraux Tumeurs
#4

Peut-on détecter les molécules stromales par imagerie ?

Des techniques d'imagerie avancées, comme l'IRM, peuvent aider à visualiser les interactions stromales.
Imagerie par résonance magnétique Interactions cellulaires
#5

Quel rôle joue la biopsie dans le diagnostic ?

La biopsie permet d'obtenir des échantillons pour analyser les interactions stromales au sein des tumeurs.
Biopsie Analyse histologique

Symptômes 5

#1

Quels symptômes sont liés aux interactions stromales ?

Les symptômes peuvent inclure douleur, inflammation et signes de progression tumorale.
Douleur Inflammation
#2

Les interactions stromales causent-elles des symptômes ?

Oui, elles peuvent influencer la croissance tumorale et provoquer des symptômes associés.
Croissance tumorale Symptômes
#3

Comment les symptômes varient-ils selon les tumeurs ?

Les symptômes dépendent du type de tumeur et de l'environnement stromal spécifique.
Tumeurs Environnement tumoral
#4

Les symptômes sont-ils précoces ou tardifs ?

Les symptômes peuvent être précoces ou tardifs, selon la nature de l'interaction stromale.
Symptômes précoces Symptômes tardifs
#5

Les symptômes sont-ils réversibles ?

Certains symptômes peuvent s'améliorer avec un traitement ciblant les interactions stromales.
Traitement Réversibilité des symptômes

Prévention 5

#1

Peut-on prévenir les interactions stromales ?

La prévention passe par la réduction des facteurs de risque liés aux tumeurs et à l'inflammation.
Prévention Facteurs de risque
#2

Quels modes de vie aident à prévenir les tumeurs ?

Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut réduire les risques.
Mode de vie sain Prévention des tumeurs
#3

Les dépistages réguliers sont-ils utiles ?

Oui, les dépistages peuvent aider à détecter les tumeurs précocement, limitant les interactions stromales.
Dépistage Détection précoce
#4

L'éducation sur le cancer est-elle importante ?

Oui, l'éducation aide à sensibiliser aux facteurs de risque et aux signes précoces de cancer.
Éducation sur le cancer Sensibilisation
#5

Les vaccins peuvent-ils prévenir les tumeurs ?

Certains vaccins, comme ceux contre le HPV, peuvent réduire le risque de cancers associés.
Vaccins Prévention du cancer

Traitements 5

#1

Quels traitements ciblent les molécules stromales ?

Des thérapies ciblées et des immunothérapies sont en développement pour cibler ces molécules.
Thérapies ciblées Immunothérapie
#2

Les traitements sont-ils efficaces ?

L'efficacité varie selon le type de tumeur et la nature des interactions stromales.
Efficacité des traitements Tumeurs
#3

Y a-t-il des effets secondaires des traitements ?

Oui, les traitements peuvent entraîner des effets secondaires, notamment des réactions immunitaires.
Effets secondaires Réactions immunitaires
#4

Comment les traitements sont-ils personnalisés ?

Les traitements sont adaptés en fonction du profil moléculaire de la tumeur et de l'environnement stromal.
Médecine personnalisée Profil moléculaire
#5

Les traitements sont-ils combinés ?

Oui, des combinaisons de traitements sont souvent utilisées pour améliorer l'efficacité.
Thérapies combinées Efficacité des traitements

Complications 5

#1

Quelles complications peuvent survenir ?

Les complications incluent la progression tumorale, la résistance au traitement et la métastase.
Complications Métastase
#2

Les interactions stromales aggravent-elles les complications ?

Oui, elles peuvent favoriser la progression tumorale et compliquer le traitement.
Progression tumorale Complications
#3

Comment gérer les complications ?

La gestion implique des traitements ciblés et un suivi régulier pour adapter les thérapies.
Gestion des complications Suivi médical
#4

Les complications sont-elles prévisibles ?

Certaines complications peuvent être anticipées en fonction du type de tumeur et des interactions.
Prévisibilité Interactions tumorales
#5

Les complications affectent-elles la qualité de vie ?

Oui, les complications peuvent significativement impacter la qualité de vie des patients.
Qualité de vie Complications

Facteurs de risque 5

#1

Quels sont les facteurs de risque des interactions stromales ?

Les facteurs incluent l'inflammation chronique, le tabagisme et des prédispositions génétiques.
Facteurs de risque Inflammation chronique
#2

L'alimentation influence-t-elle les risques ?

Oui, une alimentation riche en antioxydants peut réduire les risques d'interactions stromales.
Alimentation Antioxydants
#3

Le stress est-il un facteur de risque ?

Le stress chronique peut influencer l'inflammation et augmenter le risque de complications.
Stress Inflammation
#4

Les antécédents familiaux jouent-ils un rôle ?

Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'interactions stromales.
Antécédents familiaux Prédisposition génétique
#5

L'exposition à des toxines est-elle un risque ?

Oui, l'exposition à des substances toxiques peut favoriser les interactions stromales et le cancer.
Toxines Exposition environnementale
{ "@context": "https://schema.org", "@graph": [ { "@type": "MedicalWebPage", "name": "Molécules d'interaction stromale : Questions médicales les plus fréquentes", "headline": "Molécules d'interaction stromale : Comprendre les symptômes, diagnostics et traitements", "description": "Guide complet et accessible sur les Molécules d'interaction stromale : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.", "datePublished": "2024-01-08", "dateModified": "2025-04-02", "inLanguage": "fr", "medicalAudience": [ { "@type": "MedicalAudience", "name": "Grand public", "audienceType": "Patient", "healthCondition": { "@type": "MedicalCondition", "name": "Molécules d'interaction stromale" }, "suggestedMinAge": 18, "suggestedGender": "unisex" }, { "@type": "MedicalAudience", "name": "Médecins", "audienceType": "Physician", "geographicArea": { "@type": "AdministrativeArea", "name": "France" } }, { "@type": "MedicalAudience", "name": "Chercheurs", "audienceType": "Researcher", "geographicArea": { "@type": "AdministrativeArea", "name": "International" } } ], "reviewedBy": { "@type": "Person", "name": "Dr Olivier Menir", "jobTitle": "Expert en Médecine", "description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale", "url": "/static/pages/docteur-olivier-menir.html", "alumniOf": { "@type": "EducationalOrganization", "name": "Université Paris Descartes" } }, "isPartOf": { "@type": "MedicalWebPage", "name": "Protéines membranaires", "url": "https://questionsmedicales.fr/mesh/D008565", "about": { "@type": "MedicalCondition", "name": "Protéines membranaires", "code": { "@type": "MedicalCode", "code": "D008565", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543" } } }, "hasPart": [ { "@type": "MedicalWebPage", "name": "Molécule-1 d'interaction stromale", "alternateName": "Stromal Interaction Molecule 1", "url": "https://questionsmedicales.fr/mesh/D000071737", "about": { "@type": "MedicalCondition", "name": "Molécule-1 d'interaction stromale", "code": { "@type": "MedicalCode", "code": "D000071737", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.875.500" } } }, { "@type": "MedicalWebPage", "name": "Molécule-2 d'interaction stromale", "alternateName": "Stromal Interaction Molecule 2", "url": "https://questionsmedicales.fr/mesh/D000071738", "about": { "@type": "MedicalCondition", "name": "Molécule-2 d'interaction stromale", "code": { "@type": "MedicalCode", "code": "D000071738", "codingSystem": "MeSH" }, "identifier": { "@type": "PropertyValue", "propertyID": "MeSH Tree", "value": "D12.776.543.875.750" } } } ], "about": { "@type": "MedicalCondition", "name": "Molécules d'interaction stromale", "alternateName": "Stromal Interaction Molecules", "code": { "@type": "MedicalCode", "code": "D000071736", "codingSystem": "MeSH" } }, "author": [ { "@type": "Person", "name": "Peter B Stathopulos", "url": "https://questionsmedicales.fr/author/Peter%20B%20Stathopulos", "affiliation": { "@type": "Organization", "name": "Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca." } }, { "@type": "Person", "name": "Paul Sohn", "url": "https://questionsmedicales.fr/author/Paul%20Sohn", "affiliation": { "@type": "Organization", "name": "Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN." } }, { "@type": "Person", "name": "Wenting Wu", "url": "https://questionsmedicales.fr/author/Wenting%20Wu", "affiliation": { "@type": "Organization", "name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN." } }, { "@type": "Person", "name": "Marjan Slak Rupnik", "url": "https://questionsmedicales.fr/author/Marjan%20Slak%20Rupnik", "affiliation": { "@type": "Organization", "name": "Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria." } }, { "@type": "Person", "name": "Chih-Chun Lee", "url": "https://questionsmedicales.fr/author/Chih-Chun%20Lee", "affiliation": { "@type": "Organization", "name": "Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN." } } ], "citation": [ { "@type": "ScholarlyArticle", "name": "Statistical process control for the analysis of quality control in urodynamics: A potential new approach for quality review of urodynamics.", "datePublished": "2022-11-02", "url": "https://questionsmedicales.fr/article/36321794", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/nau.25081" } }, { "@type": "ScholarlyArticle", "name": "Use of Urodynamics by Gynecologists and Urologists in Brazil.", "datePublished": "2022-08-08", "url": "https://questionsmedicales.fr/article/35940172", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1055/s-0042-1744460" } }, { "@type": "ScholarlyArticle", "name": "US patterns of care for urodynamic evaluation for BPH.", "datePublished": "2023-07-03", "url": "https://questionsmedicales.fr/article/37395472", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1002/nau.25239" } }, { "@type": "ScholarlyArticle", "name": "Impact of deep resection of endometriosis in the pelvis on urodynamic parameters.", "datePublished": "2023-12-01", "url": "https://questionsmedicales.fr/article/38055398", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.1590/acb386323" } }, { "@type": "ScholarlyArticle", "name": "Urodynamic changes following laparoscopic versus vaginal hysterectomy.", "datePublished": "2022-09-26", "url": "https://questionsmedicales.fr/article/36165477", "identifier": { "@type": "PropertyValue", "propertyID": "DOI", "value": "10.4081/aiua.2022.3.315" } } ], "breadcrumb": { "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": 1, "name": "questionsmedicales.fr", "item": "https://questionsmedicales.fr" }, { "@type": "ListItem", "position": 2, "name": "Acides aminés, peptides et protéines", "item": "https://questionsmedicales.fr/mesh/D000602" }, { "@type": "ListItem", "position": 3, "name": "Protéines", "item": "https://questionsmedicales.fr/mesh/D011506" }, { "@type": "ListItem", "position": 4, "name": "Protéines membranaires", "item": "https://questionsmedicales.fr/mesh/D008565" }, { "@type": "ListItem", "position": 5, "name": "Molécules d'interaction stromale", "item": "https://questionsmedicales.fr/mesh/D000071736" } ] } }, { "@type": "MedicalWebPage", "name": "Article complet : Molécules d'interaction stromale - Questions et réponses", "headline": "Questions et réponses médicales fréquentes sur Molécules d'interaction stromale", "description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.", "datePublished": "2025-05-17", "inLanguage": "fr", "hasPart": [ { "@type": "MedicalWebPage", "name": "Diagnostic", "headline": "Diagnostic sur Molécules d'interaction stromale", "description": "Comment diagnostiquer une interaction stromale ?\nQuels tests sont utilisés pour les molécules stromales ?\nLes marqueurs stromaux sont-ils spécifiques ?\nPeut-on détecter les molécules stromales par imagerie ?\nQuel rôle joue la biopsie dans le diagnostic ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Urodynamics#section-diagnostic" }, { "@type": "MedicalWebPage", "name": "Symptômes", "headline": "Symptômes sur Molécules d'interaction stromale", "description": "Quels symptômes sont liés aux interactions stromales ?\nLes interactions stromales causent-elles des symptômes ?\nComment les symptômes varient-ils selon les tumeurs ?\nLes symptômes sont-ils précoces ou tardifs ?\nLes symptômes sont-ils réversibles ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Urodynamics#section-symptômes" }, { "@type": "MedicalWebPage", "name": "Prévention", "headline": "Prévention sur Molécules d'interaction stromale", "description": "Peut-on prévenir les interactions stromales ?\nQuels modes de vie aident à prévenir les tumeurs ?\nLes dépistages réguliers sont-ils utiles ?\nL'éducation sur le cancer est-elle importante ?\nLes vaccins peuvent-ils prévenir les tumeurs ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Urodynamics#section-prévention" }, { "@type": "MedicalWebPage", "name": "Traitements", "headline": "Traitements sur Molécules d'interaction stromale", "description": "Quels traitements ciblent les molécules stromales ?\nLes traitements sont-ils efficaces ?\nY a-t-il des effets secondaires des traitements ?\nComment les traitements sont-ils personnalisés ?\nLes traitements sont-ils combinés ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Urodynamics#section-traitements" }, { "@type": "MedicalWebPage", "name": "Complications", "headline": "Complications sur Molécules d'interaction stromale", "description": "Quelles complications peuvent survenir ?\nLes interactions stromales aggravent-elles les complications ?\nComment gérer les complications ?\nLes complications sont-elles prévisibles ?\nLes complications affectent-elles la qualité de vie ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Urodynamics#section-complications" }, { "@type": "MedicalWebPage", "name": "Facteurs de risque", "headline": "Facteurs de risque sur Molécules d'interaction stromale", "description": "Quels sont les facteurs de risque des interactions stromales ?\nL'alimentation influence-t-elle les risques ?\nLe stress est-il un facteur de risque ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'exposition à des toxines est-elle un risque ?", "url": "https://questionsmedicales.fr/mesh/D000071736?mesh_terms=Urodynamics#section-facteurs de risque" } ] }, { "@type": "FAQPage", "mainEntity": [ { "@type": "Question", "name": "Comment diagnostiquer une interaction stromale ?", "position": 1, "acceptedAnswer": { "@type": "Answer", "text": "Des biopsies et des analyses immunohistochimiques sont utilisées pour évaluer les interactions stromales." } }, { "@type": "Question", "name": "Quels tests sont utilisés pour les molécules stromales ?", "position": 2, "acceptedAnswer": { "@type": "Answer", "text": "Les tests ELISA et les western blots permettent de quantifier les molécules d'interaction stromale." } }, { "@type": "Question", "name": "Les marqueurs stromaux sont-ils spécifiques ?", "position": 3, "acceptedAnswer": { "@type": "Answer", "text": "Certains marqueurs peuvent être spécifiques à des types de tumeurs, mais d'autres sont plus généraux." } }, { "@type": "Question", "name": "Peut-on détecter les molécules stromales par imagerie ?", "position": 4, "acceptedAnswer": { "@type": "Answer", "text": "Des techniques d'imagerie avancées, comme l'IRM, peuvent aider à visualiser les interactions stromales." } }, { "@type": "Question", "name": "Quel rôle joue la biopsie dans le diagnostic ?", "position": 5, "acceptedAnswer": { "@type": "Answer", "text": "La biopsie permet d'obtenir des échantillons pour analyser les interactions stromales au sein des tumeurs." } }, { "@type": "Question", "name": "Quels symptômes sont liés aux interactions stromales ?", "position": 6, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent inclure douleur, inflammation et signes de progression tumorale." } }, { "@type": "Question", "name": "Les interactions stromales causent-elles des symptômes ?", "position": 7, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent influencer la croissance tumorale et provoquer des symptômes associés." } }, { "@type": "Question", "name": "Comment les symptômes varient-ils selon les tumeurs ?", "position": 8, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes dépendent du type de tumeur et de l'environnement stromal spécifique." } }, { "@type": "Question", "name": "Les symptômes sont-ils précoces ou tardifs ?", "position": 9, "acceptedAnswer": { "@type": "Answer", "text": "Les symptômes peuvent être précoces ou tardifs, selon la nature de l'interaction stromale." } }, { "@type": "Question", "name": "Les symptômes sont-ils réversibles ?", "position": 10, "acceptedAnswer": { "@type": "Answer", "text": "Certains symptômes peuvent s'améliorer avec un traitement ciblant les interactions stromales." } }, { "@type": "Question", "name": "Peut-on prévenir les interactions stromales ?", "position": 11, "acceptedAnswer": { "@type": "Answer", "text": "La prévention passe par la réduction des facteurs de risque liés aux tumeurs et à l'inflammation." } }, { "@type": "Question", "name": "Quels modes de vie aident à prévenir les tumeurs ?", "position": 12, "acceptedAnswer": { "@type": "Answer", "text": "Un mode de vie sain, incluant une alimentation équilibrée et de l'exercice, peut réduire les risques." } }, { "@type": "Question", "name": "Les dépistages réguliers sont-ils utiles ?", "position": 13, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les dépistages peuvent aider à détecter les tumeurs précocement, limitant les interactions stromales." } }, { "@type": "Question", "name": "L'éducation sur le cancer est-elle importante ?", "position": 14, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'éducation aide à sensibiliser aux facteurs de risque et aux signes précoces de cancer." } }, { "@type": "Question", "name": "Les vaccins peuvent-ils prévenir les tumeurs ?", "position": 15, "acceptedAnswer": { "@type": "Answer", "text": "Certains vaccins, comme ceux contre le HPV, peuvent réduire le risque de cancers associés." } }, { "@type": "Question", "name": "Quels traitements ciblent les molécules stromales ?", "position": 16, "acceptedAnswer": { "@type": "Answer", "text": "Des thérapies ciblées et des immunothérapies sont en développement pour cibler ces molécules." } }, { "@type": "Question", "name": "Les traitements sont-ils efficaces ?", "position": 17, "acceptedAnswer": { "@type": "Answer", "text": "L'efficacité varie selon le type de tumeur et la nature des interactions stromales." } }, { "@type": "Question", "name": "Y a-t-il des effets secondaires des traitements ?", "position": 18, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les traitements peuvent entraîner des effets secondaires, notamment des réactions immunitaires." } }, { "@type": "Question", "name": "Comment les traitements sont-ils personnalisés ?", "position": 19, "acceptedAnswer": { "@type": "Answer", "text": "Les traitements sont adaptés en fonction du profil moléculaire de la tumeur et de l'environnement stromal." } }, { "@type": "Question", "name": "Les traitements sont-ils combinés ?", "position": 20, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des combinaisons de traitements sont souvent utilisées pour améliorer l'efficacité." } }, { "@type": "Question", "name": "Quelles complications peuvent survenir ?", "position": 21, "acceptedAnswer": { "@type": "Answer", "text": "Les complications incluent la progression tumorale, la résistance au traitement et la métastase." } }, { "@type": "Question", "name": "Les interactions stromales aggravent-elles les complications ?", "position": 22, "acceptedAnswer": { "@type": "Answer", "text": "Oui, elles peuvent favoriser la progression tumorale et compliquer le traitement." } }, { "@type": "Question", "name": "Comment gérer les complications ?", "position": 23, "acceptedAnswer": { "@type": "Answer", "text": "La gestion implique des traitements ciblés et un suivi régulier pour adapter les thérapies." } }, { "@type": "Question", "name": "Les complications sont-elles prévisibles ?", "position": 24, "acceptedAnswer": { "@type": "Answer", "text": "Certaines complications peuvent être anticipées en fonction du type de tumeur et des interactions." } }, { "@type": "Question", "name": "Les complications affectent-elles la qualité de vie ?", "position": 25, "acceptedAnswer": { "@type": "Answer", "text": "Oui, les complications peuvent significativement impacter la qualité de vie des patients." } }, { "@type": "Question", "name": "Quels sont les facteurs de risque des interactions stromales ?", "position": 26, "acceptedAnswer": { "@type": "Answer", "text": "Les facteurs incluent l'inflammation chronique, le tabagisme et des prédispositions génétiques." } }, { "@type": "Question", "name": "L'alimentation influence-t-elle les risques ?", "position": 27, "acceptedAnswer": { "@type": "Answer", "text": "Oui, une alimentation riche en antioxydants peut réduire les risques d'interactions stromales." } }, { "@type": "Question", "name": "Le stress est-il un facteur de risque ?", "position": 28, "acceptedAnswer": { "@type": "Answer", "text": "Le stress chronique peut influencer l'inflammation et augmenter le risque de complications." } }, { "@type": "Question", "name": "Les antécédents familiaux jouent-ils un rôle ?", "position": 29, "acceptedAnswer": { "@type": "Answer", "text": "Oui, des antécédents familiaux de cancer peuvent augmenter le risque d'interactions stromales." } }, { "@type": "Question", "name": "L'exposition à des toxines est-elle un risque ?", "position": 30, "acceptedAnswer": { "@type": "Answer", "text": "Oui, l'exposition à des substances toxiques peut favoriser les interactions stromales et le cancer." } } ] } ] }
Dr Olivier Menir

Contenu validé par Dr Olivier Menir

Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale


Validation scientifique effectuée le 02/04/2025

Contenu vérifié selon les dernières recommandations médicales

Auteurs principaux

Peter B Stathopulos

4 publications dans cette catégorie

Affiliations :
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, London, ON, N6A 5C1, Canada. Electronic address: pstatho@uwo.ca.

Paul Sohn

3 publications dans cette catégorie

Affiliations :
  • Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN.
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.

Wenting Wu

3 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Medical and Molecular Genetics, Indiana University School of Medicine, Indianapolis, IN.

Marjan Slak Rupnik

3 publications dans cette catégorie

Affiliations :
  • Center for Physiology and Pharmacology, Medical University of Vienna, Vienna, Austria.
  • Institute of Physiology, Faculty of Medicine, University of Maribor, Maribor, Slovenia.

Chih-Chun Lee

3 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.

Tatsuyoshi Kono

3 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
  • Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.

Carmella Evans-Molina

3 publications dans cette catégorie

Affiliations :
  • Department of Anatomy, Cell Biology, and Physiology, Indiana University School of Medicine, Indianapolis, IN.
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, IN.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Pediatrics, Indiana University School of Medicine, Indianapolis, IN.
  • Richard L. Roudebush Veterans' Administration Medical Center, Indianapolis, IN.
  • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, IN.
  • Department of Medicine, Indiana University School of Medicine, Indianapolis, IN.

Mitsuhiko Ikura

2 publications dans cette catégorie

Affiliations :
  • Department of Medical Biophysics, University of Toronto, Princess Margaret Cancer Centre, University Health Network, Toronto, ON, M5G 2M9, Canada. Electronic address: mikura@uhnresearch.ca.

Matthew J Novello

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology and Pharmacology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario N6A5C1, Canada.

Seung Yeon Jeong

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
  • Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.

Jun Hee Choi

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
  • Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.

Eun Hui Lee

2 publications dans cette catégorie

Affiliations :
  • Department of Physiology, College of Medicine, The Catholic University of Korea, Seoul 06591, Korea.
  • Department of Biomedicine & Health Sciences, Graduate School, The Catholic University of Korea, Seoul 06591, Korea.

Junyang Liu

2 publications dans cette catégorie

Affiliations :
  • Xiamen University, College of Chemistry and Chemical Engineering & Innovation Laboratory for Sciences and Technologies of Energy Materials of Fujian Province (IKKEM), CHINA.

Wenjing Hong

2 publications dans cette catégorie

Affiliations :
  • Xiamen University, College of Chemistry and Chemical Engineering, Siming south road 422, 3012, Xiamen, CHINA.

Farooq Syed

2 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Staci A Weaver

2 publications dans cette catégorie

Affiliations :
  • Center for Diabetes and Metabolic Diseases, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Herman B Wells Center for Pediatric Research, Indiana University School of Medicine, Indianapolis, Indiana, USA.
  • Department of Biochemistry and Molecular Biology, Indiana University School of Medicine, Indianapolis, Indiana, USA.

Garrick Chang

2 publications dans cette catégorie

Affiliations :
  • Department of Physics, Indiana University Indianapolis, Indianpolis, Indiana, USA.

Jing Liu

2 publications dans cette catégorie

Affiliations :
  • Department of Physics and Astronomy, Purdue University, West Lafayette, Indiana, USA.

Eman Salem Algariri

1 publication dans cette catégorie

Affiliations :
  • Universiti Sains Malaysia, Advanced Medical and Dental Institute, Department of Biomedical Science, Pulau Pinang, Malaysia
  • Hadhramout University, Faculty of Medicine and Health Sciences, Department of Basic Medical Sciences, Hadhramout, Yemen
Publications dans "Molécules d'interaction stromale" :

Rabiatul Basria S M N Mydin

1 publication dans cette catégorie

Affiliations :
  • Universiti Sains Malaysia, Advanced Medical and Dental Institute, Department of Biomedical Science, Pulau Pinang, Malaysia
Publications dans "Molécules d'interaction stromale" :

Sources (256 au total)

Statistical process control for the analysis of quality control in urodynamics: A potential new approach for quality review of urodynamics.

To analyze quality control in urodynamic studies, using a proportion control chart (p-chart) for statistical process control.... This single-center study was conducted at the Urodynamic Center of West China Hospital, Sichuan University. We randomly selected 15 samples from each month in 2020, and 180 urodynamic traces were fina... All data points of each artefact were within zone A. However, one outlier was found in the p-chart of all artefacts in October, which might have been caused by inexperienced operators.... Statistical process control may play an important role in the process control of urodynamic studies and guide us in identifying the cause of poor quality in process management....

Use of Urodynamics by Gynecologists and Urologists in Brazil.

Urodynamic studies (UDSs) are a set of tests that assess the storage and emptying of urine, and they are widely used by gynecologists and urologists in the management of urinary incontinence (UI), des... The present is an opinion survey applied from August 2020 to January 2021 through a semistructured questionnaire about the clinical practice sent by e-mail to all participants. The responses were comp... Of the 329 participants, 238 were gynecologists (72.3%) and 91, urologists (27.7%). Most gynecologists (73.5%) and urologists (86.6%) do not request UDSs before the conservative treatment of UI; but U... Most Brazilian gynecologists and urologists who participated in the present study do not request UDSs before the conservative treatment of UI, according to national and internacional guidelines, and o...

US patterns of care for urodynamic evaluation for BPH.

Practice patterns around the use of urodynamic evaluation (UDS) for benign prostatic hyperplasia (BPH) surgery are largely undefined. As such, we investigated factors associated with the use of UDS fo... We used American Board of Urology case log data from 2008 to 2020, to compare patient- and surgeon-sided factors associated with UDS utilization and BPH surgeries. We performed logistic regression mod... Among urologists performing UDS, the majority (80%) self-identified as general urologists and practiced in a private practice group (69%). Compared with urologists who performed no UDS, urologists who... There is a significant practice variation in use of UDS for BPH. Although overall BPH surgeries are increasing, urologists are increasingly less likely to perform UDS for BPH. Specifically, urologists...

Impact of deep resection of endometriosis in the pelvis on urodynamic parameters.

To evaluate the effects of deep resection of endometriosis in the posterior pelvic region on urodynamic parameters.... A prospective observational study conducted with female patients diagnosed with deep pelvic endometriosis before and after endometriosis resection surgery. Clinical history, image exams, the Female Lo... Patients aged 30-39 years old, operative duration of 132.5 minutes, and 2.7 days of hospital stay. Uroflowmetry and cystometry showed tendency for an increase after the surgery in the flow duration, t... A significant response in the patient's perception of urinary function was demonstrated after surgery. It is observed that the surgical procedure did not affect the uroflowmetric and cystometric chara...

Urodynamic changes following laparoscopic versus vaginal hysterectomy.

To compare urodynamic changes before and after hysterectomy (laparoscopic vs. vaginal approach) for benign gynecological diseases.... A total of 90 women with a mean age of 56.36-years were enrolled in this study between August 2019 and April 2021. They were divided into two equal groups (45 patients each). Group, I had a vaginal hy... Both vaginal and laparoscopic hysterectomy did not significantly change the maximum flow rate, voiding time, and average flow rate. The increase in residual urine volume in group I was not significant (p ... According to the urodynamic study, hysterectomy for benign uterine conditions, whether vaginal or laparoscopic did not adversely affect urinary bladder function....

Long-term urodynamic findings following colo-, gastro- and ileocystoplasty.

To evaluate the urodynamic changes in patients who have undergone colocystoplasty (CCP), gastrocystoplasty (GCP) and ileocystoplasty (ICP) in a retrospective study. Changes in urinary continence, inci... Eighty-four patients were included in the study who underwent bladder augmentation between 1987 and 2017. Group I: 35 patients with CCP. Group II: 18 patients with GCP. Group III: 31 patients with ICP... In Group I, two patients and in Group III, one patient remained incontinent after CCP and ICP. Bladder capacity increased significantly, maximal intra-vesical pressure decreased and compliance improve... From the urodynamic point of view, ileum is the most adequate option in the long term. Contractions after augmentation might be caused by the remaining peristalsis of the detubularised segment. Furthe...

Early urodynamic findings after complete primary repair of exstrophy.

Detrusor contraction in bladder exstrophy (BE) patients following reconstruction is poorly understood as there are few published studies assessing urodynamic findings in this population. Understanding... We sought to evaluate early detrusor contraction using urodynamic studies (UDS) in children who had previously undergone complete primary repair of bladder exstrophy (CPRE). We hypothesized that a maj... A retrospective review of our prospectively collected database was performed for all patients with a diagnosis of classic BE who underwent primary CPRE between 2013 and 2017. From this cohort we ident... There were 50 children (31 male, 19 female) with CBE who underwent CPRE between 2013 and 2017.There were 26 (13 male, 13 female) who met inclusion criteria. Median age was 3.5 (IQR: 3.2-4.7) years at ... We present the first study assessing early UDS finding of detrusor contraction in BE patients after CPRE. In our cohort, 61.5% of patients were able to generate a sustained detrusor contraction on UDS... At short term follow up, the majority of children in our cohort were able to produce sustained detrusor contractions sufficient to generate a void per urethra with a modest post void residual volume. ...

Evaluation of urodynamic pattern in short and long-standing diabetic patients.

To address the pattern of urodynamic findings in diabetic patients with lower urinary tract symptoms (LUTS), comparing short-standing and long-standing type 2 diabetes mellitus (T2DM).... A prospective study was conducted on 50 patients presenting with LUTS and a concurrent diagnosis of T2DM, between February 2016 and May 2018. Patients were classified and evaluated according to the du... A total of 50 patients were included in the study. The mean duration of T2DM was 10 ± 0.7 years. The mean age was 56.3 ± 1.2 years, and the mean HbA1c was 7.5 ± 1.2%. Urodynamic evaluation detected si... There are different patterns in urodynamic characterizations of T2DM. Patients with short-standing DM present more commonly with storage symptoms and detrusor overactivity on urodynamics. Contrastingl...

Dipstick urinalysis does not predict post-urodynamic study morbidity.

Pre-procedure urinalysis may add unnecessary cost and inconvenience for patients undergoing urodynamics. The hypothesis of this study was that urinalysis would perform poorly when predicting complicat... Case-control study of women aged 18-89 undergoing urodynamics from 01 January2008 to 31 December 2017 at two tertiary medical centers. Data collected included patient demographics, past medical histor... A total of 601 patients met the criteria; 11 of these experienced an adverse event, of which all were a urinary tract infection. There were no differences in the frequency of adverse events based on a... The frequency of adverse events after urodynamics is low, and urinalysis in asymptomatic patients does not seem to be useful in predicting morbidity....

Comparison of the Effectiveness of Pre-urodynamic Single-dose Levofloxacin with Post-urodynamic Levofloxacin for Three Days Related to the Incidence of Urinary Tract Infection: A Randomized Control Trial.

The current study aims to compare the effectiveness of pre-urodynamic single-dose levofloxacin and post-urodynamic levofloxacin for three days related to the incidence of urinary tract infections post... This is a single-blind randomized clinical trial conducted in three outpatient urology centers in Jakarta: Cipto Mangunkusumo General Hospital, Siloam Asri Hospital, and Persahabatan General Hospital ... A total of 126 patients (63 patients in each arm) were included in the evaluation and analysis. Overall, urinary tract infections were detected in 25 cases (19.8%), 12 patients from the pre-urodynamic... There is no significant difference between a single dose of 500 mg of Levofloxacin administered one hour before the urodynamic study and a once-daily dose of 500 mg of Levofloxacin for three days foll...